• Vitreoretinal surgeons can now benefit from access to BVI's high-quality ISPAN^TM ophthalmic gases, supporting the critical needs of advanced retinal procedures.
• This latest development leverages BVI’s U.S. distribution network to ensure faster, more efficient delivery to surgeons and clinics.

WALTHAM, Mass., August 11, 2025 – BVI Medical, a leading global ophthalmic device company at the forefront of advancements in eye surgery, today announced its official launch of ISPAN^TM ophthalmic gases.  This is the first ever introduction by BVI of retinal gases for the US market. Read More

• The Council will serve as an advisory group, guiding BVI on corporate strategy, unmet clinical needs, product development, and surgical best practices.
• This initiative marks a key step in BVI’s global expansion, with plans underway for a European Surgical Advisory Board to further strengthen international partnerships

WALTHAM, Mass., August 6th, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the formation of its first U.S. Surgical Leadership Council. This distinguished group of seven leaders spans the fields of cataract, retina, and glaucoma surgery—each dedicated to shaping the future of ophthalmology through collaboration and insight-driven innovation. Read More

• BVI’s Leos™ system has been used clinically for the first time, marking a major milestone following its FDA 510(k) clearance in April 2025.
• Leos™ is the first and only FDA-cleared laser system with advanced digital endoscopic visualization for ab interno intraocular pressure reduction.

WALTHAM, Mass., July 31, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced the first clinical use of its FDA-cleared Leos™ Laser Endoscopy Ophthalmic System. The milestone procedure was performed by Dr. Nathan Radcliffe, a glaucoma specialist at the Ambulatory Surgery Center of Greater New York, Bronx, NY. Read More

• BVI received four awards in the 2025 Medical Device Network Excellence Awards—for Innovation, Product Launches, R&D, and Investments—recognizing its leadership in advancing ophthalmic technology and global growth.
• Key achievements include the launch of SERENITY IOLs with ISOFOCAL technology, FDA clearance of the Leos™ glaucoma system, and a $1 billion capital raise supporting strategic expansion and continued innovation.

WALTHAM, Mass., July 9th, 2025 – BVI, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, has been recognized with four prestigious accolades in the 2025 Medical Device Network Excellence Awards. The company earned top honors in Innovation, Research and Development, Investments, and Product Launches, underscoring its leadership in advancing eye care technology, strategic growth, and breakthrough product development. Read More

• This clearance marks a significant advancement in glaucoma care, especially for earlier stages of the disease and across a wide spectrum of glaucoma types.
• This novel, proprietary laser-based system features a unique mechanism of action.
• Designed to deliver vibrant, high-quality visualization of eye anatomy.
• Broad commercialization is planned for 2025.

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) – BVI Medical, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative glaucoma surgical system, Leos™ (Laser Endoscopy Ophthalmic System) Read More